Philippe A. Cassier - Publications, H-index & Citations

Philippe A. Cassier

Centre Léon Bérard

60H指数

541论文数

1.7W被引数

收录论文 176

发表时间

Advancing antibody drug conjugates in gastrointestinal cancers 胃肠道癌症中抗体药物偶联物的进展

British Journal of Cancer

IF6.8

2026-07-23

PREAI

Philippe A. Cassier; Floriane Izarn; Charles Dumontet; Clélia Coutzac

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study 肿瘤局部CD40激动与MP0317，一种FAP x CD40 DARPin，重新编程晚期实体瘤患者的肿瘤微环境: 一项开放标签，非随机，剂量递增的1期研究

Nature Cancer

IF28.5

2026-05-01

OAAI

Neeltje Steeghs; Carlos Gomez-Roca; Iphigénie Korakis; Eelke Gort; Hilde De Winter; Nina Stojcheva; Vaia Stavropoulou; Jennifer Krieg; Paul Baverel; Elena Fernandez; Ana Maria Florescu; Lea Hoenig; Michael Peter Sanderson; Vladimir Kirkin; Philippe Legenne; Philippe Alexandre Cassier

Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study 帕博利珠单抗单药治疗微卫星高度不稳定或错配修复缺陷型复发性胶质瘤：来自多队列KEYNOTE-158研究的结果

Journal of Neuro-Oncology

IF3.1

2026-04-01

PREAI

Capucine Baldini; Philippe A. Cassier; Jean-Pierre Delord; Matteo Simonelli; Mehdi Touat; Lili Yao; J. Paul Duic; Alexander Gozman; Aurelien Marabelle

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study 奥罗玛西布（olomorasib）对KRAS G12C突变型晚期实体瘤的泛瘤活性：一项首次人体研究

Nature Communications

IF15.7

2026-03-12

OAAI

Yonina R. Murciano-Goroff; Antoine Hollebecque; Rebecca S. Heist; Philippe A. Cassier; Ji-Youn Han; So Yeon Kim; Joshua K. Sabari; Diego Tosi; Adrian Sacher; Timothy F. Burns; Toshio Shimizu; Natraj Reddy Ammakkanavar; Alexander Spira; Carlos Gomez-Roca; Amita Patnaik; Rasha Cosman; J. Nicholas Bodor; Misako Nagasaka; Arthur Xintian You; Samuel C. McNeely; Raimund Peter; Aaron Fink; Aaron Chen; Geoffrey R. Oxnard; Melinda D. Willard; Yasutoshi Kuboki; Takafumi Koyama

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours W0180作为抗-VISTA单克隆抗体，在局部晚期或转移性实体瘤患者中的首次人体1期剂量递增研究，包括单独使用和联合帕博利珠单抗

BMJ Oncology

IF0

2026-02-01

OAAI

Gomez-Roca, Carlos; Champiat, Stephane; Danlos, Francois-Xavier; Castanon Alvarez, Eduardo; Cassier, Philippe Alexandre; Dupuy, Elena; Jegou, David; Primard, Marie; Petain, Aurelie; Saccareau, Mathilde; Gueguen-Dorbes, Genevieve; Fabre, Claire; Marabelle, Aurelien; Melero, Ignacio

Integrated palliative care with early clinical trial: what oncologists say and what patients understand

Supportive Care in Cancer

IF3

2026-01-26

PREAI

Mathilde Lochmann; Magali Girodet; Johanna Despax; Valentine Baudry; Julie Duranti; Bénédicte Mastroianni; Hélène Vanacker; Armelle Vinceneux; Mehdi Brahmi; Olivier Renard; Loïc Verlingue; Aurélie Swadulz; Mona Amini-Adle; Julien Gautier; Françoise Ducimetière; Amélie Anota; Philippe A. Cassier; Gisèle Chvetzoff; Véronique Christophe

Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC 奥罗莫西布与帕博利珠单抗联合治疗KRAS G12C突变型晚期非小细胞肺癌的疗效与安全性

Journal of Thoracic Oncology

IF20.8

2025-11-29

PREAI

Timothy F. Burns; Natraj Reddy Ammakkanavar; Antoine Hollebecque; Dae Ho Lee; Takafumi Koyama; Philippe A. Cassier; Antoine Italiano; Ji-Youn Han; Nimit Singhal; Shinji Takeuchi; Rebecca S. Heist; Dustin Deming; Alexander Spira; Quincy Chu; Adrian Sacher; Yutaka Fujiwara; Michael J. Chisamore; Arthur Xintian You; Samuel C. McNeely; Aaron Fink

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1 CD40激动剂米他扎利单抗联合mFOLFIRINOX治疗未治疗转移性胰腺癌：OPTIMIZE-1研究中与结局相关的生物标志物

Cell Reports Medicine

IF10.6

2025-10-07

OAAI

Jean-Luc Van Laethem; Karen Geboes; Ivan Borbath; Teresa Macarulla Mercade; Aurélien Lambert; Philippe Cassier; Hans Prenen; Emmanuel Mitry; Jean-Frédéric Blanc; Lorenzo Pilla; Jaime Feliu; Mercedes Rodriguez Garrote; Roberto Antonio Pazo-Cid; Inmaculada Gallego; Karin Enell Smith; Karin Nordbladh; David Gomez Jimenez; Peter Ellmark; Yago Pico de Coaña; Sumeet Vijay Ambarkhane; Gregory L. Beatty; Eileen M. O'Reilly

Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers GSK3326595的1b期和剂量扩展研究，PRMT5抑制剂作为单一疗法并与Pembrolizumab联合用于晚期癌症患者

Annals of Oncology

IF65.4

2025-09-09

PREAI

M.M. Gounder; P. Martin-Romano; A. Italiano; L.L. Siu; P.A. Cassier; G.S. Falchook; I.S. Lossos; D.W. Rasco; J.F. Hilton; M.A. McKean; F.L. Opdam; J. Strauss; M. De Jonge; J.S.P. Vermaat; T. Crossman; M. Zajac; A. Tarkar; F. Gonzalez Carreras; B.E. Kremer; O. Barbash; S. Segal; R. Parasrampuria; S. Postel-Vinay

Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement 解决肿瘤学早期临床试验中的筛查失败问题：对病人结局的影响及改进策略

ESMO Open

IF8.3

2025-08-13

OAAI

I. Korakis; K. Ouali; B. Hanvic; L. Verlingue; B. Allignet; A. Lusque; S. Clementei; E. Magne; C. Massard; J.-P. Delord; P. Cassier; C. Baldini; B. Segier; C. Gomez-Roca

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort 伦伐替尼联合帕博利珠单抗用于先前接受过治疗的特定实体瘤患者：来自LEAP-005研究复发胶质母细胞瘤队列的2期研究结果

Cancer

IF5.1

2025-08-13

OAAI

Sun Young Rha MD, PhD; Eduardo Castanon MD; Sanjeev Gill MBBS, FRACP; Helene Senellart MD; Juanita Lopez MD, PhD; Iván Márquez-Rodas MD, PhD; Iván Victoria MD; Tae Min Kim MD, PhD; Zarnie Lwin MBBS, FCP, FRACP; Michael C. Burger MD; Matteo Simonelli MD; Philippe A. Cassier MD, PhD; Andrew E. Hendifar MD; Paolo A. Ascierto MD; Corina Dutcus MD; Chinyere E. Okpara PhD; Razi Ghori PhD; Fan Jin MD; Roman Groisberg MD; Luis Villanueva MD, MSc

Selpercatinib in the treatment of thyroid cancer 塞尔佩卡替尼在甲状腺癌治疗中的应用

Future Oncology

IF2.6

2025-07-10

PREAI

Thibault Gauduchon; Romain Varnier; Philippe A. Cassier

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis 瑞戈非尼联合阿维鲁单抗在晚期胃肠胰神经内分泌肿瘤中的应用：一项II期试验及相关分析

NATURE CANCER

IF28.5

2025-04-09

PREAI

Cousin, Sophie; Guegan, Jean-Philippe; Palmieri, Lola Jade; Metges, Jean Philippe; Pernot, Simon; Bellera, Carine A.; Assenat, Eric; Korakis, Iphigenie; Cassier, Philippe Alexandre; Hollebecque, Antoine; Cantarel, Coralie; Kind, Michele; Soubeyran, Isabelle; Sokol, Harry; Vanhersecke, Lucile; Bessede, Alban

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial 帕博利珠单抗在微卫星高度不稳定和错配修复缺陷型晚期实体瘤中的研究：KEYNOTE-158试验的更新结果

NATURE CANCER

IF28.5

2025-02-20

PREAI

Marabelle, Aurelien; O'Malley, David M.; Hendifar, Andrew E.; Ascierto, Paolo A.; Motola-Kuba, Daniel; Penel, Nicolas; Cassier, Philippe A.; Bariani, Giovanni; De Jesus-Acosta, Ana; Doi, Toshihiko; Longo, Federico; Miller, Wilson H.; Oh, Do-Youn; Gottfried, Maya; Yao, Lili; Jin, Fan; Gozman, Alexander; Maio, Michele

Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results 帕博利珠单抗在微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）和非微卫星高度不稳定/非错配修复缺陷（non-MSI-H/non-dMMR）晚期子宫内膜癌中的疗效：KEYNOTE-158研究II期结果

gynecologic oncology

IF4.1

2025-02-01

PREAI

O'Malley, David M.; Bariani, Giovani M.; Cassier, Philippe A.; Marabelle, Aurelien; Hansen, Aaron R.; Acosta, Ana De Jesus; Miller Jr, Wilson H.; Safra, Tamar; Italiano, Antoine; Mileshkin, Linda; Yao, Lili; Gozma, Alexander; Jin, Fan; Maio, Michele

Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1+antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics 通过空间转录组学和血浆蛋白质组学鉴定与胃癌anti-PD-1/PD-L1抗血管生成相关的微环境特征

MOLECULAR CANCER

IF33.9

2024-09-13

OAAI

Cousin, Sophie; Guegan, Jean-Philippe; Shitara, Kohei; Palmieri, Lola Jade; Metges, Jean Philippe; Pernot, Simon; Fukuoka, Shota; Koyama, Shohei; Nishikawa, Hiroyoshi; Bellera, Carine A.; Adenis, Antoine; Gomez-Roca, Carlos A.; Cassier, Philippe Alexandre; Hollebecque, Antoine; Cantarel, Coralie; Kind, Michele; Soubeyran, Isabelle; Vanhersecke, Lucile; Bessede, Alban; Italiano, Antoine

A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors 一项评估exarafenib（一种选择性泛RAF抑制剂）联合binimetinib治疗NRAS突变（NRASMut）黑色素瘤（Mel）和BRAF变异实体瘤的I期临床试验。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Cassier, P.; Mehnert, J. M.; Kim, R.; Chmielowski, B.; Millward, M.; Perez, C. A.; Gonzalez Cao, M.; Gambardella, V.; Mckean, M.; Brose, M. S.; Xing, Y.; Long, G. V.; Kelly, A.; Lee, G.; Severson, P.; Williams, R.; Marqueste, C. Gaudy

Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST Ribociclib/HDM201 basket study 晚期高分化/去分化脂肪肉瘤 (WD/DD LPS) 和其他分子选择癌症患者 (pt) 的Siremadlin (S) 和ribociclib (R): MEGAMOST Ribociclib/HDM201篮子研究的最终分析

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Brahmi, M.; Tredan, O.; Gomez-Roca, C. A.; Italiano, A.; Saada, E. B.; Bertucci, F.; Le Cesne, A.; Cassier, P.; Treilleux, I.; Chabaud, S.; Garin, G. Fournier; Perol, D.; Blay, J-Y.; Dufresne, A.

Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors CFT1946的I期研究初步结果，CFT1946是一种新型BIDAC降解剂，用于突变型BRAF V600实体瘤。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Vieito, M.; Mckean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Moreno Garcia, V.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; Korakis, I.; Van Tine, B. A.; Ma, V. T-L.; Ali, A.; Hinojosa, E.; Lobbardi, R.; Liu, H.; Hurh, E.; Reyno, L.; Buchbinder, E.

Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors BT-001（一种表达抗CTLA4单克隆抗体的溶瘤病毒）作为单药及联合pembrolizumab给药在晚期实体瘤患者中的初步临床结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Champiat, S.; Lebbe, C.; Baurain, J-F.; Italiano, A.; Sakkal, M.; Spring-Giusti, C.; Stojkowitz, N.; Brandely, M.; Sadoun, A.; Ropenga, A.; Semmrich, M.; McAllister, A.; Chisamore, M.; Cassier, P.

研究方向